Genomic Profiles Analysis in Children, Adolescents and Young Adult With Sarcomas
Sponsor: Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant'Anna · NCT04621201 on ClinicalTrials.gov ↗
Conditions studied
What it tests
- observation and biopsyother
Where it's running10 sites
10 international sites
- Recruiting now
AOU Città della Salute e della Scienza di Torino - Presidio Infantile Regina Margherita
Torino, Turin, Italy 10126
- Celeste Cagnazzo, PhD(contact)00390113135171[email protected]
- Recruiting now
Istituto Ortopedico Rizzoli
Bologna, Italy
- Emanuela Palmerini(contact)
- Recruiting now
Policlinico S.Orsola-Malpighi
Bologna, Italy
- Arcangelo Prete(contact)
- Recruiting now
Azienda ospedaliero-universitaria Meyer
Florence, Italy
- Angela Tamburrini(contact)
- Recruiting now
Istituto Giannina Gaslini
Genova, Italy
- Alberto Garaventa(contact)
- Recruiting now
Istituto Nazionale Tumori
Milan, Italy
- Roberto Luksch(contact)
- Suspended
Presidio Ospedaliero Gaetano Pini | ASST Pini-CTO
Milan, Italy
- Recruiting now
Fondazione I.R.C.C.S. Policlinico San Matteo
Pavia, Italy
- Marco Zecca(contact)
- Active, not recruiting
Istituti fisioterapici Ospitalieri - Istituto Tumori Regina Elena e Istituto Dermatologico San Gallicano
Roma, Italy
- Recruiting now
IRCCS materno infantile Burlo Garofolo
Trieste, Italy
- Marco Rabusin(contact)
See the official eligibility language
Shown exactly as written on ClinicalTrials.gov. Your oncologist is the right person to judge whether it fits your situation.
Inclusion Criteria: 1. Patients with histologically confirmed Osteosarcoma, Ewing Sarcoma or Synovial Sarcoma at first diagnosis. 2. Patients with confirmed relapsed/refractory Osteosarcoma, Ewing Sarcoma or Synovial Sarcoma 3. Written informed consent signed by the patient, or parents or legal representative to perform molecular analysis of the tumor sample. 4. Patients aged ≤24 years 5. Pathological review of tumor samples. 6. Availability of fresh tumor sample from newly diagnosed or relapsed/refractory cancer and 10 ml of EDTA peripheral blood sample. Centralization of paraffin-embedded tumor sample might be optional. Exclusion Criteria: * 1\. Known history of active HIV, HCV, or HBV infection 2. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient undergoing surgery biopsy or the quality of the data.
Updated 2023-03-29 on ClinicalTrials.gov. Always confirm current details with the study team or your oncologist.